HB661 (2020) Detail

(New Title) relative to claims for medical monitoring.


HB 661 - AS AMENDED BY THE HOUSE

 

8Jan2020... 2766h

2019 SESSION

19-0816

06/03

 

HOUSE BILL 661

 

AN ACT relative to claims for medical monitoring.

 

SPONSORS: Rep. Cushing, Rock. 21; Rep. Stack, Hills. 21; Rep. W. Thomas, Hills. 21; Rep. Murphy, Hills. 21; Rep. Keans, Straf. 23; Rep. Grassie, Straf. 11; Rep. Meuse, Rock. 29; Rep. Janvrin, Rock. 37; Rep. Oxenham, Sull. 1; Sen. Feltes, Dist 15; Sen. Sherman, Dist 24; Sen. Chandley, Dist 11; Sen. Fuller Clark, Dist 21

 

COMMITTEE: Judiciary

 

-----------------------------------------------------------------

 

AMENDED ANALYSIS

 

This bill establishes the elements of a claim for medical monitoring and the damages that may be awarded.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

8Jan2020... 2766h 19-0816

06/

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Nineteen

 

AN ACT relative to claims for medical monitoring.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  New Chapter; Claims for Medical Monitoring.  Amend RSA by inserting after chapter 125-S the following new chapter:

CHAPTER 125-T

CLAIMS FOR MEDICAL MONITORING

125-T:1  Purpose.  The general court finds that a claim for medical monitoring is consistent with currently existing common law in the state of New Hampshire and other jurisdictions.  The purpose of this chapter is to make the remedy of medical monitoring damages more uniform and better address the needs of those exposed.

125-T:2  Definitions.  In this chapter:

I.  "Exposure" means ingestion, inhalation, contact with skin or eyes, or any other physical contact.

II.  "Hazardous or toxic substance" means any chemical or biological substance that is categorized as toxic, or an equivalent, by the United States Environmental Protection Agency (EPA) or the Agency for Toxic Substance and Disease Registry (ATSDR) of the United States Department of Health and Human Services.  Chemical or biological substances which are not so categorized may be proven to be hazardous or toxic by a preponderance of the evidence by expert testimony.

125-T:3  Elements of Claim.  

I.  In order to prove a claim for medical monitoring damages, the plaintiff must show by a preponderance of the evidence for each of the following that:

(a)  The defendant negligently caused significant exposure to a proven hazardous or toxic substance;

(b)  The plaintiff now suffers from an increased risk of illness, disease, or latent disease.  The plaintiff does not need to prove that the illness, disease, or latent disease is certain or likely to develop as a result of the exposure;

(c)  The increased risk under subparagraph (b) makes the need for diagnostic testing reasonably necessary; and

(d)  Medical tests exist to detect the illness, disease, or latent disease.

II.  A claim for medical monitoring damages may be made without proof of present physical injury or symptoms.

III.  Present or past health status shall not be at issue in a claim for medical monitoring.

125-T:4  Damages.

I.  Damages shall be limited to reasonably necessary periodic examinations and related costs.  The costs and necessity of such examinations shall be proven by expert testimony.

II.  If medical monitoring relief is awarded, a court may place the award into a court-supervised program administered by one or more medical professionals.

III.  Upon an award of medical monitoring damages, the court may award to the plaintiff reasonable attorney's fees and other litigation costs reasonably incurred.

125-T:5  Statute of Limitation.  Medical monitoring claims shall be made with 3 years of the effective date of this chapter or discovery of exposure.  The date when the hazardous or toxic substance was released is immaterial for purposes of this section.

125-T:6  Severability.  If any provision of this chapter or the application thereof to any person or circumstances is held invalid, such invalidity shall not affect other provisions or applications of the chapter which can be given effect without the invalid provision or application, and to this end the provisions of this chapter are declared to be severable.

2  Effective Date.  This act shall take effect upon its passage.

Links

HB661 at GenCourtMobile
HB661 Discussion

Action Dates

Date Body Type
Jan. 30, 2019 House Hearing
March 5, 2019 House Exec Session
Oct. 29, 2019 House Exec Session
House Floor Vote

Bill Text Revisions

HB661 Revision: 7911 Date: Jan. 9, 2020, 11:49 a.m.
HB661 Revision: 7379 Date: Jan. 16, 2019, 9:42 a.m.

Docket

Date Status
Jan. 3, 2019 Introduced 01/03/2019 and referred to Judiciary HJ 3 P. 24
Jan. 30, 2019 Public Hearing: 01/30/2019 01:00 pm LOB 208
Feb. 26, 2019 Full Committee Work Session: 02/26/2019 10:00 am LOB 208
March 5, 2019 Executive Session: 03/05/2019 11:00 am LOB 208
Retained in Committee
June 11, 2019 Subcommittee Work Session: 06/11/2019 09:30 am LOB 208
Aug. 27, 2019 Subcommittee Work Session: 08/27/2019 10:00 am LOB 208
Sept. 17, 2019 Subcommittee Work Session: 09/17/2019 10:00 am LOB 208
Oct. 3, 2019 Subcommittee Work Session: 10/03/2019 10:00 am LOB 208
Oct. 15, 2019 Subcommittee Work Session: 10/15/2019 01:00 pm LOB 208
Oct. 29, 2019 Executive Session: 10/29/2019 11:00 am LOB 208
Majority Committee Report: Ought to Pass with Amendment # 2019-2766h (NT) (Vote 16-3; RC) HC 50
Minority Committee Report: Inexpedient to Legislate
Jan. 8, 2020 Amendment # 2019-2766h (NT): AA VV 01/08/2020 HJ 1 P. 131
Jan. 8, 2020 Ought to Pass with Amendment 2019-2766h (NT): MA VV 01/08/2020 HJ 1 P. 131
March 11, 2020 Introduced 03/11/2020 and Referred to Judiciary; SJ 7
June 16, 2020 Vacated from Committee and Laid on Table, MA, VV; 06/16/2020 SJ 8
June 16, 2020 No Pending Motion; 06/16/2020 SJ 8